Department of General Surgery, Breast Disease Center, Department of Radiology, Huaxi MR Research Center (HMRRC), Liver Transplant Center, Laboratory of Liver Transplantation, Key Laboratory of Transplant Engineering and Immunology, NHC, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
Adv Mater. 2024 Aug;36(35):e2405075. doi: 10.1002/adma.202405075. Epub 2024 Aug 13.
Bacterial-derived micro-/nanomedicine has garnered considerable attention in anticancer therapy, owing to the unique natural features of bacteria, including specific targeting ability, immunogenic benefits, physicochemical modifiability, and biotechnological editability. Besides, bacterial components have also been explored as promising drug delivery vehicles. Harnessing these bacterial features, cutting-edge physicochemical and biotechnologies have been applied to attenuated tumor-targeting bacteria with unique properties or functions for potent and effective cancer treatment, including strategies of gene-editing and genetic circuits. Further, the advent of bacteria-inspired micro-/nanorobots and mimicking artificial systems has furnished fresh perspectives for formulating strategies for developing highly efficient drug delivery systems. Focusing on the unique natural features and advantages of bacteria, this review delves into advances in bacteria-derived drug delivery systems for anticancer treatment in recent years, which has experienced a process from living entities to artificial mimicking systems. Meanwhile, a summary of relative clinical trials is provided and primary challenges impeding their clinical application are discussed. Furthermore, future directions are suggested for bacteria-derived systems to combat cancer.
细菌衍生的微/纳米医学在抗癌治疗中受到了广泛关注,这是由于细菌具有独特的天然特征,包括特定的靶向能力、免疫原性益处、物理化学可修饰性和生物技术可编辑性。此外,细菌成分也被探索为有前途的药物输送载体。利用这些细菌特性,先进的物理化学和生物技术已应用于具有独特特性或功能的减毒肿瘤靶向细菌,以实现强效和有效的癌症治疗,包括基因编辑和遗传电路策略。此外,细菌启发的微/纳米机器人和模仿人工系统的出现为制定高效药物输送系统的策略提供了新的视角。本综述聚焦于细菌的独特天然特征和优势,深入探讨了近年来细菌衍生的抗癌药物输送系统的进展,该领域经历了从活体到人工模拟系统的发展过程。同时,提供了相关临床试验的总结,并讨论了阻碍其临床应用的主要挑战。此外,还为细菌衍生系统对抗癌症提出了未来的发展方向。